Company: OSRH
Filing Date: 2025-04-22
Form Type: 10-K
Source: 0001213900-25-034116
Chunk: 1237

Company: OSR Holdings, Inc.
Filing Date: 2025-04-22
Form: 10-K
Item: Item 5
Chunk 1237
---
 positions for Shinhan Securities Co. Ltd., in South Korea. Mr. Bang is a certified public accountant
in the U.S., a certified credit analyst in Korea and a certified investment manager in Korea. Mr. Bang received his B.A. in Business
Administration from Hansung University in 2002.

Dr. Constance Höfer has been the Chief Scientific Officer
of the Company since March 24, 2025. Dr. Höfer is a seasoned leader in drug development with over 20 years of experience in oncology
and immunology and will oversee OSR Holdings’ scientific strategy and innovation pipeline. Dr. Höfer joins OSR Holdings from
Merck Healthcare, where she led global programs spanning from preclinical to late-stage clinical development. Prior to Merck, she held
senior leadership positions at Sandoz Biopharmaceuticals, Priaxon AG, and Medigene AG, playing a key role in advancing therapeutic programs
across various modalities, including New Biological Entities (NBEs), New Chemical Entities (NCEs), nucleotides, and viral and cell-based
therapies. Coupled with her extensive industry experience and a PhD in Pharmacology from the University of Newcastle, Dr. Höfer has
a strong foundation in clinical pharmacology and translational medicine, ensuring a seamless transition from early-stage research to successful
clinical development.

Phil Geon Lee has been a Director of the Company since May 2024.
Mr. Lee possesses over 20 years of experience in legal and investment fields. His areas of expertise cover a range of fund classes,
including regulatory, transactional, and hedge funds, and encompass knowledge of financial regulatory frameworks in various jurisdictions
such as the SEC (US), FCA (UK), MAS (Singapore), CSSF (Luxembourg), and FSS (Korea). His legal career includes significant experience
in handling litigations and disputes in securities, consumer protection, antitrust laws across multiple countries including Korea, U.S.,
Germany, France, Japan, Poland, etc. Mr. Lee’s transactional experience includes managing over 300 deals in private equity
and real estate transactions. Mr. Lee currently holds the position of Managing Director at IGIS (May 2023-Present), the largest
real estate investment adviser in Korea (AUM US $48 billion). His previous roles include Chief Compliance Officer at IKR Co., Ltd.
(a joint venture between IGIS Asset Management and K